Alnylam Pharma has been riding high since revealing top-line results from its HELIOS-B trial of vutrisiran in transthyretin-mediated amyloidosis (ATTR) – but a look at the full data seems t
Bayer has shored up its near-term pipeline by acquiring European rights to acoramidis from BridgeBio and Eidos Therapeutics, putting some big pharma muscle behind the ther
Our round-up of recent biotech financings is headed by a massive $1.25 billion round for genetic medicines specialist BridgeBio Pharma, with smaller rounds for Tr1X, Coman